CYTKCytokinetics, Incorporated
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, heavy debt (BB), and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$13.7M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -72% · now 26% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can CYTK take a bad year?
Cytokinetics, Incorporated holds $890M more cash than debt, and is burning $145M a quarter, about 2.0 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- -1.02
Altman Z-score · distress zone, below 1.8
- Cash runway
- 2.0 years
Cash runway · burning $145M a quarter at the current rate
Details›
- Total debtQ2 2026
- $276M
- Cash and short-term investments
- $1.17B
- Net cash
- $890M
- EBITDA, trailing twelve months
- −$695M
- Operating profit, trailing twelve months
- −$708M
- Annualised volatilitytwo years of daily moves
- 55%
- Worst drawdown on file
- −72%
- Below its 52-week high
- 26%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.